Protagonist Therapeutics Announces FDA Approval For ICOTYDE, IL-23 Receptor Antagonist For Treatment Of Moderate-To-Severe Plaque Psoriasis; Treatment Commercialized Under License By Johnson & Johnson

Benzinga Newsdesk www.benzinga.com Positive 90.4%

Neg 0% Neu 0% Pos 90.4%

Comments

No comments yet. Be the first!